<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">128</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2012-0-4-26-29</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THYROID HORMONE THERAPY PRINCIPLES AFTER SURGERY OF THYROID TUMORS</article-title><trans-title-group xml:lang="ru"><trans-title>ПРИНЦИПЫ ГОРМОНАЛЬНОЙ ТЕРАПИИ ПОСЛЕ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ НОВООБРАЗОВАНИЙ ЩИТОВИДНОЙ ЖЕЛЕЗЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vanushko</surname><given-names>V. E.</given-names></name><name xml:lang="ru"><surname>Ванушко</surname><given-names>В. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fadeev</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Фадеев</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rumyantsev</surname><given-names>P. O.</given-names></name><name xml:lang="ru"><surname>Румянцев</surname><given-names>П. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>rumyantsev.pavel@endocrincentr.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FSBI “Endocrinology Research Center”, Ministry of Health of Russia, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБУ «Эндокринологический научный центр» Минздрава России, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2012</year></pub-date><volume>2</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>26</fpage><lpage>29</lpage><history><date date-type="received" iso-8601-date="2015-04-19"><day>19</day><month>04</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-04-19"><day>19</day><month>04</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Vanushko V.E., Fadeev V.V., Rumyantsev P.O.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Ванушко В.Э., Фадеев В.В., Румянцев П.О.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Vanushko V.E., Fadeev V.V., Rumyantsev P.O.</copyright-holder><copyright-holder xml:lang="ru">Ванушко В.Э., Фадеев В.В., Румянцев П.О.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/128">https://ogsh.abvpress.ru/jour/article/view/128</self-uri><abstract xml:lang="en"><p>Thyroid hormone administration after thyroid tumors surgery is a part of complex treatment strategy. In case of papillary, follicular and poor-differentiated carcinomas suppressive treatment regime is indicated with target TSH level &amp;le; 0.1 IU/l. Intensity and duration of TSH suppressive treatment regime depends on tumor recurrence risk group and presence of severe cardio-vascular disease. In case of medullary and anaplastic thyroid cancer require substitutive treatment regime as well as after benign tumor surgery. If patient has been undergone partial thyroid resection by reason of benign tumor the suppressive treatment necessity would be settled in terms of postsurgical TSH level. Thereafter on substitutive or suppressive L-thyroxine treatment patient has achieved target TSH level the further control of it is conducting half in year and annually later. </p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>thyroid</kwd><kwd>tumors</kwd><kwd>hormone therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>щитовидная железа</kwd><kwd>опухоли</kwd><kwd>гормональная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list/></back></article>
